Last reviewed · How we verify
dexmedetomidine 3
Dexmedetomidine, marketed by First Affiliated Hospital, Sun Yat-Sen University, is an established drug in the healthcare market with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | dexmedetomidine 3 |
|---|---|
| Also known as | Dex,Dexmedetomidine |
| Sponsor | First Affiliated Hospital, Sun Yat-Sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Effect of CYP2D6 on Perioperative Analgesia of Oxycodone in Elderly Patients
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries (PHASE4)
- PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults (NA)
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |